IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation

[1]  V. Costa,et al.  The Multifaceted Role of Annexin A1 in Viral Infections , 2023, Cells.

[2]  D. Yoon,et al.  Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis , 2017, Theranostics.

[3]  W. Dinjens,et al.  Tissue inhibitor of metalloproteinase-3 (TIMP3) expression decreases during melanoma progression and inhibits melanoma cell migration. , 2016, European journal of cancer.

[4]  Zhijie Kang,et al.  CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer , 2016, Scientific Reports.

[5]  N. Sheikh,et al.  IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis , 2016, Mediators of inflammation.

[6]  L. Joosten,et al.  Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. , 2016, Carcinogenesis.

[7]  J. Shim,et al.  Polymorphisms in PRKCDBP, a Transcriptional Target of TNF-α, Are Associated With Inflammatory Bowel Disease in Korean , 2015, Intestinal research.

[8]  D. Matei,et al.  TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells , 2014, Epigenetics.

[9]  R. Edwards,et al.  Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3 , 2014, British Journal of Cancer.

[10]  G. Mann,et al.  TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells , 2014, Oncotarget.

[11]  P. V. van Diest,et al.  HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation , 2014, Cancer medicine.

[12]  Shi-fang Sun,et al.  TGF-β1, IL-6, and TNF-α in Bronchoalveolar Lavage Fluid: Useful Markers for Lung Cancer? , 2014, Scientific Reports.

[13]  Jun Li,et al.  IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. , 2014, Carcinogenesis.

[14]  D. Y. Hwang,et al.  Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development , 2014, Oncogene.

[15]  L. Qin,et al.  Challenging role of Wnt5a and its signaling pathway in cancer metastasis (Review) , 2014, Experimental and therapeutic medicine.

[16]  G. Mincione,et al.  The antitumor potential of Interleukin-27 in prostate cancer , 2013, Oncotarget.

[17]  J. Wands,et al.  Role of NADPH oxidase NOX5-S, NF-κB, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells. , 2013, American journal of physiology. Cell physiology.

[18]  L. Yarmus,et al.  Interleukin-6 cytokine: a multifunctional glycoprotein for cancer. , 2013, Immunome research.

[19]  Sukgil Song,et al.  Lung tumor growth-promoting function of peroxiredoxin 6. , 2013, Free radical biology & medicine.

[20]  A. Rashid,et al.  Characterization of interleukin-1β in Helicobacter pylori-induced gastric inflammation and DNA methylation in interleukin-1 receptor type 1 knockout (IL-1R1(-/-)) mice. , 2013, European journal of cancer.

[21]  L. Tsai,et al.  Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer. , 2012, The American journal of pathology.

[22]  A. Rashid,et al.  Helicobacter pylori induces promoter methylation of E‐cadherin via interleukin‐1β activation of nitric oxide production in gastric cancer cells , 2012, Cancer.

[23]  A. Hartmann,et al.  Gastrointestinal , Hepatobiliary , and Pancreatic Pathology Methylation-Dependent Activation of CDX 1 through NF-B A Link from Inflammation to Intestinal Metaplasia in the Human Stomach , 2012 .

[24]  Hao Wang,et al.  Detection of TIMP3 Promoter Hypermethylation in Salivary Rinse as an Independent Predictor of Local Recurrence-Free Survival in Head and Neck Cancer , 2012, Clinical Cancer Research.

[25]  Philip Smith,et al.  Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1 , 2011, Oncogene.

[26]  M. Borrello,et al.  TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells , 2011, Oncogene.

[27]  H. J. Kim,et al.  IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals , 2011, Oncogene.

[28]  P. Conti,et al.  IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. , 2010, European journal of dermatology : EJD.

[29]  J. Goldberg,et al.  Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. , 2010, Future oncology.

[30]  W. Xiao,et al.  Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy , 2009, Current genomics.

[31]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[32]  Tamara Cacev,et al.  Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. , 2008, Carcinogenesis.

[33]  J. S. Rao,et al.  Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. , 2008, Cancer research.

[34]  P. Malfertheiner,et al.  Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. , 2008, Neoplasia.

[35]  A. Takayanagi,et al.  Epithelial overexpression of interleukin‐32α in inflammatory bowel disease , 2007 .

[36]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[37]  M. Sonobe,et al.  Expression of tissue inhibitor of metalloproteinase‐3 (TIMP‐3) and its prognostic significance in resected non‐small cell lung cancer , 2007, Journal of surgical oncology.

[38]  P. Youinou,et al.  Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). , 2007, Autoimmunity reviews.

[39]  R. Khokha,et al.  Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3−/− mice , 2006, Oncogene.

[40]  C. Dinarello,et al.  IL-32, a novel cytokine with a possible role in disease , 2006, Annals of the rheumatic diseases.

[41]  C. Wild,et al.  Tissue inhibitor of metalloproteinase‐3 (TIMP‐3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosis , 2005, International journal of cancer.

[42]  Mitsutoshi Nakamura,et al.  Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas , 2005, Laboratory Investigation.

[43]  D. Yoon,et al.  Interleukin-32: a cytokine and inducer of TNFalpha. , 2005, Immunity.

[44]  B. Fingleton,et al.  Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration , 2004, Nature Genetics.

[45]  S. Jee,et al.  Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency , 2001, Oncogene.

[46]  J. Herman,et al.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. , 1999, Cancer research.

[47]  E. Wouters,et al.  The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment. , 1998, Respiratory medicine.

[48]  A. Fulton,et al.  Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. , 1997, Cellular immunology.

[49]  C. Bucana,et al.  Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  E. Maxwell,et al.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism , 1996, The Journal of experimental medicine.